Do Results Make Hikma Pharmaceuticals Plc A Better Bet Than AstraZeneca plc And GlaxoSmithKline plc?

Could Hikma Pharmaceuticals Plc (LON: HIK) dethrone AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Who is the real competitor to AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK)? In an obvious way they’re competing with each other and with the other major blockbuster drug researchers around the world. But it was a very different kind of competition that laid them low a few years ago and has led to increased efforts to get their development pipelines stuffed with as many candidates as possible.

It was the ending of patent protection on key drugs that did it, followed by competition from makers of generic alternatives that can be sold for much lower prices. And one such company, Hikma Pharmaceuticals (LSE: HIK), reported a strong first half on Wednesday, with its shares picking up 3% on the day to reach 2,496p — and over 12 months they’re up 33%, easily beating AstraZeneca and GlaxoSmithKline’s, erm, nothing.

Small fish

With a market capitalization of around £4.8bn, Hikma is small fry compared to its big cousins, but it’s risen from its debut on the London Stock Exchange in 2005 to the lower reaches of the FTSE 100 today. And if things continues as well as CEO Said Darwazah, who described the period as “an excellent start to the year” seems to think, it’s surely still on its way up.

The manufacture of branded medications saw a revenue jump of 16% to $282m (in constant currency), although overall revenue fell by 4% — largely because of an expected fall in revenue from unbranded generics. Adjusted earnings per share dropped 20% to 71.4 cents, and the overall interim dividend was maintained at a very well covered 11 cents per share.

The key thing for Hikma is its acquisitions progress, and we heard that the integration of assets acquired from US injectables firm Bedford Laboratories has gone smoothly, and that the acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane should make it the sixth largest generics manfuacturer in the US — not bad for a company founded as recently as 1978 in Amman in Jordan.

Great growth potential?

Looking forward, Hikma’s P/E of 27 clearly includes a greater growth premium than either AstraZeneca’s 16 or GlaxoSmithKline’s slightly headier 18, and Hikma offers a much smaller dividend yield — under 1%, while Astra is set to pay 4.2% and Glaxo 6.6%.

Glaxo’s dividend, however, won’t be covered by earnings, and it’s set to keep paying it out of cash reserves while it continues its pipeline-growing activities. And Astra’s dividend will only be covered around 1.5 times, with boss Pascal Soriot’s impressive drive for recovery still not likely to bring about a return to earnings growth before 2017 — some had been hoping for 2016, but that’s looking less and less likely.

And while the two biggies are still fighting to get back on track, if Hikma can carry on successfully reinvesting its cash to grow its business and expand globally — well, looking back in another five years could show something very different to today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »